Follow-up of blood-pressure lowering and glucose control in type 2 diabetes

New England Journal of Medicine

Volumn 371, Issue 15, 2014, Pages 1392-1406

  Zoungas, Sophia ^a,c   Chalmers, John ^a   Neal, Bruce ^a   Billot, Laurent ^a   Li, Qiang ^a   Biostat, M ^r   Hirakawa, Yoichiro ^a   Arima, Hisatomi ^a   Monaghan, Helen ^a   Joshi, Rohina ^a   Colagiuri, Stephen ^b   Cooper, Mark E ^d   Glasziou, Paul ^f   Grobbee, Diederick ^g   Hamet, Pavel ^h   Harrap, Stephen ^e   Heller, Simon ⁱ   Lisheng, Liu ^m   Mancia, Giuseppe ⁿ   Marre, Michel ^o   Matthews, David R ^j   Mogensen, Carl E ^p   Perkovic, Vlado ^a   Poulter, Neil ^k   Rodgers, Anthony ^a   Williams, Bryan ^l   MacMahon, Stephen ^a   Patel, Anushka ^a   Woodward, Mark ^a,q   more..

^a GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^b Boden Institute   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f BOND UNIVERSITY   (Australia)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ UNIVERSITY OF SHEFFIELD   (United Kingdom)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m Chinese Hypertension League Institute   (China)

ⁿ UNIVERSITY OF MILANO BICOCCA   (Italy)

^o UNIVERSITÉ PARIS DESCARTES   (France)

^p AARHUS UNIVERSITY HOSPITAL   (Denmark)

^q JOHNS HOPKINS UNIVERSITY   (United States)

^r NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; GLUCOSE; INDAPAMIDE PLUS PERINDOPRIL; PLACEBO; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; GLYCOSYLATED HEMOGLOBIN; INDAPAMIDE; INDAPAMIDE, PERINDOPRIL DRUG COMBINATION; PERINDOPRIL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SURVIVAL; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GLICLAZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INDAPAMIDE; MALE; MIDDLE AGED; PERINDOPRIL; RISK FACTORS;

EID: 84907862963     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1407963     Document Type: Article

References (14)

1. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
3. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359: 1565-76.
4. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007;370:829-40.
5. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
6. Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013;83:517-23.
7. ADVANCE Management Committee. Study rationale and design of ADVANCE: Action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia 2001;44:1118-20.
8. Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments. Lancet 2005;365:1591-5.
9. Kostis WJ, Thijs L, Richart T, Kostis JB, Staessen JA. Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure- lowering medications. Hypertension 2010;56:1060-8.
10. Appel LJ, Wright JT Jr, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010;363:918-29.
11. Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 2012;344: d7541.
12. Brouwers FP, Asselbergs FW, Hillege HL, et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J 2011;161:1171-8.
13. Kostis WJ, Cabrera J, Messerli FH, et al. Competing cardiovascular and noncardiovascular risks and longevity in the Systolic Hypertension in the Elderly Program. Am J Cardiol 2014;113:676-81.
14. Hata J, Arima H, Zoungas S, et al. Effects of the endpoint adjudication process on the results of a randomised controlled trial: The ADVANCE trial. PLoS One 2013; 8(2):e55807.